Health TrialsbyHealthPanel

Nutritional Indices and Inflammatory Markers in MASLD

ConditionsLiver FibrosisMalnutritionNon-Alcoholic Fatty Liver Disease
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorAssiut University

About this trial

Metabolic Dysfunction-Associated steatotic Liver Diseases MASLD affects approximately 25 percent of population. Systemic inflammation plays role in MASLD progression. This cross-sectional observational study at Assiut University Hospitals will include 180 participants aged 18 to 65 years divided into 90 with MASLD and 90 without MASLD over one year. Nutritional indices Prognostic Nutritional Index PNI and Controlling Nutritional Status CONUT score will be calculated from albumin lymphocyte count and cholesterol. CBC-based inflammatory indices SIRI SII PIV PWR PLR MPR WNR NLR will be calculated. MASLD fibrosis score based on age BMI diabetes AST ALT ratio platelet albumin and FibroScan will assess fibrosis F0-F2 versus F3-F4. Aim to evaluate correlation between PNI CONUT and MASLD and role of inflammatory indices as predictors for MASLD and advanced fibrosis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 to 65 years

Written informed consent

Disqualifiers

Acute infection

Major surgery or recent trauma within the last 6 months

Known malignancy

Previous history of bariatric surgery

Trial population

Adults aged 18-65 years attending Assiut University Hospitals, divided into those with MASLD and those without MASLD.

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

180 Participants
are grouped into 2 trial groups
Group A: MASLD
Group B: Non-MASLD

Trial outcomes

Primary outcomes

1

Correlation Between Prognostic Nutritional Index PNI and MASLD Presence

PNI calculated as 10 x serum albumin g per dL plus 0.005 x total lymphocyte count per mm3 will be compared between MASLD and non-MASLD groups to evaluate association with MASLD presence

Time frame
Baseline

Secondary outcomes

1

Predictive Value of CBC-Derived Inflammatory Indices SIRI SII PIV for MASLD

SIRI neutrophil x monocyte divided by lymphocyte, SII platelet x neutrophil divided by lymphocyte, PIV neutrophil x monocyte x platelet divided by lymphocyte will be calculated and ROC curve analysis performed to detect role as predictors for MASLD

Time frame
Baseline
2

Predictive Value of PLR NLR MPR PWR for Liver Fibrosis Severity

PLR platelet lymphocyte ratio, NLR neutrophil lymphocyte ratio, MPR monocyte platelet ratio, PWR platelet WBC ratio and platelet albumin ratio will be correlated with MASLD fibrosis score and FibroScan results to predict advanced fibrosis F3-F4 versus F0-F2

Time frame
Baseline
3

MASLD Fibrosis Score and FibroScan for Advanced Fibrosis

MASLD NAFLD fibrosis score based on age BMI diabetes AST ALT ratio platelet albumin with cutoffs less than -1.455 absence and greater than 0.675 presence of significant fibrosis. FibroScan measurement of liver stiffness in kPa. Correlation with nutritional and inflammatory indices

Time frame
Baseline

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: